A Phase I, Single Ascending and Multiple Ascending Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LIFE-001
Latest Information Update: 07 Jan 2026
At a glance
- Drugs LIFE 001 (Primary)
- Indications Immunological disorders; Transplant rejection
- Focus Adverse reactions
- Sponsors LifeMine Therapeutics
Most Recent Events
- 10 Dec 2025 Planned number of patients changed from 100 to 120.
- 10 Dec 2025 Planned End Date changed from 31 Jan 2026 to 31 Mar 2026.
- 10 Dec 2025 Planned primary completion date changed from 31 Jan 2026 to 31 Mar 2026.